Page last updated: 2024-11-12
bluensomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
bluensomycin: differs from dihydrostreptomycin only in absence of guanidino group; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 20055290 |
| CHEMBL ID | 2104642 |
| CHEBI ID | 81193 |
| SCHEMBL ID | 691672 |
| MeSH ID | M0049533 |
Synonyms (25)
| Synonym |
|---|
| u 12898 |
| bluensin |
| d-scyllo-inositol, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1=>2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1=>2)-1-((aminoiminomethyl)amino)-1-deoxy-, 5-carbamate |
| bluensomycin [inn] |
| antibiotic obtained from cultures of streptomyces verticillus, or the same substance produced by any other means |
| bluensomycine [inn-french] |
| u 12898d |
| u-12898 |
| bluensomicina [inn-spanish] |
| bluensomycinum [inn-latin] |
| 11011-72-6 |
| bluensomycin |
| C17573 |
| lwv7pwe57u , |
| bluensomicina |
| bluensomycinum |
| bluensomycine |
| unii-lwv7pwe57u |
| CHEMBL2104642 |
| chebi:81193 , |
| SCHEMBL691672 |
| Q27155138 |
| gtpl10765 |
| u12898 |
| [(1r,2s,3s,4r,5r,6r)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl] carbamate |
Research Excerpts
Overview
Bluensomycin (glebomycin) is an aminocyclitol antibiotic. It differs structurally from dihydrostreptomycin in having bluensidine (1D-1-O-carbamoyl-3-guanidinodeoxy-scyllo-inositol) rather than streptidine.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bluensomycin (glebomycin) is an aminocyclitol antibiotic that differs structurally from dihydrostreptomycin in having bluensidine (1D-1-O-carbamoyl-3-guanidinodeoxy-scyllo-inositol) rather than streptidine (1,3-diguanidino-1,3-dideoxy-scyllo-inositol) as its aminocyclitol moiety. " | ( Possible evolutionary relationships between streptomycin and bluensomycin biosynthetic pathways: detection of novel inositol kinase and O-carbamoyltransferase activities. Walker, JB, 1990) | 1.96 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| amino sugar | Any sugar having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||